TSE:VPH Valeo Pharma (VPH) Stock Price, News & Analysis → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free VPH Stock Alerts C$0.08 -0.01 (-5.88%) (As of 06/7/2024 08:54 PM ET) Add Compare Share Share Today's RangeC$0.08▼C$0.0950-Day RangeC$0.08▼C$0.1652-Week RangeC$0.06▼C$0.41Volume31,839 shsAverage Volume67,000 shsMarket CapitalizationC$7.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsHeadlinesStock AnalysisChartCompetitorsEarningsHeadlines Get Valeo Pharma alerts: Email Address Ad Oasis GoldExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About Valeo Pharma Stock (TSE:VPH)Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, a flavonoid formulation used for immune support; Ethacrynate Sodium; and Amikacin, an antibiotic. In addition, the company provides Ametop Gel 4% for skin anesthesia prior to injection or cannulation; Sabizabulin, an antiviral and anti-inflammatory agent for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, a prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory/allergy, ophthalmology, neurology, oncology, and specialty products. The company was incorporated in 2003 and is based in Kirkland, Canada.Read More VPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VPH Stock News HeadlinesJune 6, 2024 | americanbankingnews.comValeo Pharma (VPH) to Release Earnings on ThursdayMay 5, 2024 | finance.yahoo.comBullish Valeo Pharma Insiders Loaded Up On CA$1.20m Of StockApril 9, 2024 | finance.yahoo.comVALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCEApril 1, 2024 | theglobeandmail.comValeo Pharma: Top 25 Undervalued Toronto Stock Exchange Stocks (VPH)March 22, 2024 | finance.yahoo.comVALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORSMarch 16, 2024 | markets.businessinsider.comValeo Pharma’s Strategic Moves Signal Potential for EBITDA Positivity and Stock CatalystsMarch 14, 2024 | finance.yahoo.comVALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTSMarch 7, 2024 | finance.yahoo.comVALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCASTFebruary 14, 2024 | uk.finance.yahoo.comNews Flash: 2 Analysts Think Valeo Pharma Inc. (TSE:VPH) Earnings Are Under ThreatFebruary 13, 2024 | finance.yahoo.comVALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGESFebruary 3, 2024 | msn.comBiden to release proposed U.S. budget plan on March 11February 2, 2024 | finance.yahoo.comVALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LPJanuary 29, 2024 | finance.yahoo.comVALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023January 22, 2024 | finance.yahoo.comVALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCASTDecember 16, 2023 | morningstar.comValeo Pharma Inc Ordinary Shares VPHDecember 11, 2023 | theglobeandmail.comClosing Bell: Valeo Pharma Inc 12.0 Pct Debs flat on Wednesday (VPH-DB)November 27, 2023 | theglobeandmail.comValeo Pharma: Top 10 Undervalued Drug Manufacturers Industry Stocks (VPH)November 21, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN) and Valeo Pharma (OtherVPHIF)November 21, 2023 | finance.yahoo.comValeo Pharma announces new chief financial officer along with $2 million in cost reductionsNovember 20, 2023 | finance.yahoo.comVALEO PHARMA ANNOUNCES ORGANIZATIONAL CHANGES AND COST REDUCTION INITIATIVESNovember 9, 2023 | theglobeandmail.comValeo Pharma: Bottom 25 Performing Stocks Year-to-Date on TSX (VPH)November 7, 2023 | finance.yahoo.comVALEO PHARMA ANNOUNCES APPOINTMENT OF MR. RICHARD LAJOIE TO BOARD OF DIRECTORSNovember 6, 2023 | theglobeandmail.comClosing Bell: Valeo Pharma Inc 12.0 Pct Debs down on Friday (VPH-DB)October 20, 2023 | theglobeandmail.comValeo Pharma: Top 10 Undervalued Growth Stocks on TSX (VPH)October 14, 2023 | theglobeandmail.comValeo Pharma: Top 10 Undervalued Nano Cap Stocks on TSX (VPH)See More Headlines Receive VPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Valeo Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today6/09/2024Next Earnings (Confirmed)6/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:VPH CUSIPN/A CIKN/A Webwww.valeopharma.com Phone514-694-0150FaxN/AEmployees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-28,430,000.00 Net Margins-52.37% Pretax MarginN/A Return on EquityN/A Return on Assets-23.07% Debt Debt-to-Equity RatioN/A Current Ratio0.49 Quick RatioN/A Sales & Book Value Annual SalesC$54.29 million Price / Sales0.15 Cash FlowN/A Price / Cash FlowN/A Book ValueC($0.48) per share Price / Book-0.17Miscellaneous Outstanding Shares98,660,000Free FloatN/AMarket CapC$7.89 million OptionableNot Optionable Beta2.59 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Steven Saviuk CA (Age 65)Vice Chairman, President & CEO Comp: $250kMr. Kyle SteigerSenior VP & Chief Commercial OfficerMr. Pascal TougasChief Financial OfficerMr. Frederic DumaisDirector of Communications & Investor RelationsMr. Guy-Paul AllardVP of Legal Affairs & Corporate SecretaryMr. Jean Francois FournierHead of Ophthalmology Business UnitMore ExecutivesKey CompetitorsMedexus PharmaceuticalsTSE:MDPViridium Pacific GroupCVE:VIRZomedica Pharmaceuticals Corp. (ZOM.V)CVE:ZOMCharlotte's WebTSE:CWEBInMed PharmaceuticalsTSE:INView All Competitors VPH Stock Analysis - Frequently Asked Questions How have VPH shares performed in 2024? Valeo Pharma's stock was trading at C$0.18 at the start of the year. Since then, VPH stock has decreased by 55.6% and is now trading at C$0.08. View the best growth stocks for 2024 here. When is Valeo Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024. View our VPH earnings forecast. How were Valeo Pharma's earnings last quarter? Valeo Pharma Inc. (TSE:VPH) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm earned $13.54 million during the quarter, compared to analyst estimates of $15.30 million. How do I buy shares of Valeo Pharma? Shares of VPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:VPH) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valeo Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Valeo Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.